MX2016009491A - Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. - Google Patents
Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.Info
- Publication number
- MX2016009491A MX2016009491A MX2016009491A MX2016009491A MX2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A
- Authority
- MX
- Mexico
- Prior art keywords
- dpp4
- antagonist
- disorder
- specific
- biomarker
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title abstract 3
- 208000006673 asthma Diseases 0.000 title abstract 2
- 101150093210 DPP4 gene Proteins 0.000 title 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 title 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 210000004072 lung Anatomy 0.000 title 1
- 230000002093 peripheral effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 4
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 4
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931878P | 2014-01-27 | 2014-01-27 | |
| US201461990932P | 2014-05-09 | 2014-05-09 | |
| PCT/US2015/012885 WO2015112970A1 (en) | 2014-01-27 | 2015-01-26 | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016009491A true MX2016009491A (es) | 2017-01-13 |
Family
ID=53682019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009491A MX2016009491A (es) | 2014-01-27 | 2015-01-26 | Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160363591A1 (enExample) |
| EP (2) | EP3685857A1 (enExample) |
| JP (1) | JP2017509692A (enExample) |
| KR (1) | KR20160113700A (enExample) |
| CN (1) | CN105934254A (enExample) |
| AU (1) | AU2015209124A1 (enExample) |
| BR (1) | BR112016017192A2 (enExample) |
| CA (1) | CA2937387A1 (enExample) |
| MX (1) | MX2016009491A (enExample) |
| RU (1) | RU2016134838A (enExample) |
| SG (1) | SG11201606102UA (enExample) |
| WO (1) | WO2015112970A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015214103A1 (en) * | 2014-02-07 | 2016-07-21 | Abbott Laboratories | Novel assay to detect human periostin |
| KR20170098941A (ko) | 2015-01-09 | 2017-08-30 | 메디뮨 엘엘씨 | 인간 dpp-4를 검출하기 위한 검정법 |
| JP2018538249A (ja) * | 2015-11-04 | 2018-12-27 | アストラゼネカ アクチボラグ | 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| JP6995844B2 (ja) * | 2016-09-23 | 2022-02-04 | ジェネンテック， インコーポレイテッド | アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用 |
| WO2018156734A1 (en) * | 2017-02-24 | 2018-08-30 | Trustees Of Boston University | Isolation of human lung progenitors derived from pluripotent stem cells |
| CN109055522A (zh) * | 2018-07-03 | 2018-12-21 | 吉林大学 | C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用 |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
| CN113155996A (zh) * | 2021-03-23 | 2021-07-23 | 广州医科大学附属第一医院（广州呼吸中心） | 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用 |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| EP1631680A2 (en) * | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| CA2558366A1 (en) * | 2004-02-23 | 2005-09-01 | Erasmus Universiteit Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
| BRPI0720280A2 (pt) * | 2006-12-11 | 2014-01-28 | Wyeth Corp | Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13 |
| WO2008091814A2 (en) * | 2007-01-22 | 2008-07-31 | Wyeth | Assessment of asthma and allergen-dependent gene expression |
| US20120005206A1 (en) * | 2007-02-09 | 2012-01-05 | Konstantinos Anagnostakis | Apparatus and method for analysis of data traffic |
| CN102099485A (zh) * | 2007-10-23 | 2011-06-15 | 临床基因组学有限公司 | 诊断新生物的方法-ⅱ |
| RU2607569C2 (ru) | 2008-03-31 | 2017-01-10 | Дженентек, Инк. | Композиции и способы для лечения и диагностики астмы |
| US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| JP2013544235A (ja) * | 2010-10-15 | 2013-12-12 | メドイミューン・リミテッド | 肺機能を改善する治療法 |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| US8961965B2 (en) | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
-
2015
- 2015-01-26 KR KR1020167023637A patent/KR20160113700A/ko not_active Withdrawn
- 2015-01-26 EP EP20158832.4A patent/EP3685857A1/en not_active Withdrawn
- 2015-01-26 SG SG11201606102UA patent/SG11201606102UA/en unknown
- 2015-01-26 BR BR112016017192A patent/BR112016017192A2/pt not_active IP Right Cessation
- 2015-01-26 CA CA2937387A patent/CA2937387A1/en not_active Abandoned
- 2015-01-26 RU RU2016134838A patent/RU2016134838A/ru not_active Application Discontinuation
- 2015-01-26 JP JP2016566866A patent/JP2017509692A/ja active Pending
- 2015-01-26 EP EP15740660.4A patent/EP3099323A4/en not_active Withdrawn
- 2015-01-26 AU AU2015209124A patent/AU2015209124A1/en not_active Abandoned
- 2015-01-26 US US15/114,467 patent/US20160363591A1/en not_active Abandoned
- 2015-01-26 MX MX2016009491A patent/MX2016009491A/es unknown
- 2015-01-26 CN CN201580005884.2A patent/CN105934254A/zh active Pending
- 2015-01-26 WO PCT/US2015/012885 patent/WO2015112970A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016134838A (ru) | 2018-03-07 |
| CA2937387A1 (en) | 2015-07-30 |
| EP3685857A1 (en) | 2020-07-29 |
| EP3099323A4 (en) | 2017-10-04 |
| SG11201606102UA (en) | 2016-08-30 |
| EP3099323A1 (en) | 2016-12-07 |
| RU2016134838A3 (enExample) | 2018-09-27 |
| BR112016017192A2 (pt) | 2017-10-10 |
| CN105934254A (zh) | 2016-09-07 |
| AU2015209124A1 (en) | 2016-08-18 |
| WO2015112970A1 (en) | 2015-07-30 |
| JP2017509692A (ja) | 2017-04-06 |
| US20160363591A1 (en) | 2016-12-15 |
| KR20160113700A (ko) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016009491A (es) | Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. | |
| WO2016077366A8 (en) | Therapeutic and diagnostic methods for il-33-mediated disorders | |
| WO2013008102A3 (en) | Methods and compositions for evaluating and/or treating chronic immune diseases | |
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| MX2016014624A (es) | Metodos para el tratamiento de enfermedad inflamatoria del intestino. | |
| MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
| MX2017003954A (es) | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr. | |
| MX2016002879A (es) | Sistemas, dispositivos y metodos para la terapia anti-tl1a. | |
| HK1255922A1 (zh) | 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子 | |
| NZ602618A (en) | Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders | |
| WO2010118243A3 (en) | Use of il-27 antagonists to treat lupus | |
| AR084831A1 (es) | Terapia anticancer mediante inhibidores de quinasa | |
| MX2013000675A (es) | Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer. | |
| EP3683320A3 (en) | Mirna fingerprint in the diagnosis of lung cancer | |
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| IN2012DN06588A (enExample) | ||
| IN2014DN08537A (enExample) | ||
| PH12015502687A1 (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| WO2011128820A3 (en) | Methods for the analysis of breast cancer disorders | |
| WO2011156000A3 (en) | Use of il-4/il-13 antagonists to treat eosinophilic disorders | |
| WO2014023808A3 (en) | Method for evaluating a cancer patient for propensity to respond to a therapy | |
| HK1229236A1 (en) | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung | |
| UA116615C2 (uk) | Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем | |
| WO2012078648A3 (en) | Novel method of cancer diagnosis and prognosis and prediction of response to therapy |